Courtney Flaherty

An NDA for rivoceranib plus camrelizumab in frontline HCC has been resubmitted to the FDA, following the company's receipt of 2 CRLs for this indication.

The FDA has approved a 375-mg vial of nelarabine for intravenous administration in both T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

The novel oral fascin inhibitor NP-G2-044 received FDA orphan drug designation for patients with pancreatic cancer.

Raji Shameem, MD, discusses the significance of data from the phase 2 ILUSTRO trial of biomarker-guided triplet therapy in gastric and GEJ adenocarcinoma.

The FDA has approved the Guardant360 CDx as a companion diagnostic for encorafenib in patients with mCRC harboring BRAF V600E mutations.

Maxwell Lloyd, MD, details the implications of DESTINY-Breast11 and DESTINY-Breast05 data for the use of T-DXd in early-stage HER2-positive breast cancer.

Breast cancer experts convened during an OncLive Scientific Interchange and Workshop to discuss the evolving use of oral SERDs in ER-positive breast cancer.

Sofi-cel has received FDA breakthrough therapy designation for heavily pretreated patients with relapsed/refractory T-ALL and T-LBL.

Erica L. Mayer, MD, MPH, discusses updated data with CDK4/6 inhibitors and ongoing investigations of oral SERDs in HR-positive breast cancer.

ICT01 has received FDA breakthrough therapy designation as frontline therapy for patients with AML who are unfit for induction chemotherapy.

The autologous tumor-cell immunotherapy improved OS and RFS vs placebo in patients who achieved a CR after undergoing surgery and frontline chemotherapy.

Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.

A BLA for ivonescimab plus chemotherapy in EGFR-mutant NSCLC following treatment with a third-generation EGFR TKI has been submitted to the FDA.

Enolen, a localized enzalutamide–eluting implant, has received FDA fast track designation for low- to intermediate-risk, localized prostate cancer.

Orca-T improved clinical outcomes both overall and across patient subgroups with varied demographic and clinical features in the Precision-T trial.

HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.

Tsewang Tashi, MD, expands on long-term bone health data with avapritinib in patients with indolent systemic mastocytosis from the PIONEER trial.

The first-in-class, CXCR4hi regulatory T-cell therapy CK0804 received orphan drug designation for patients with myelofibrosis.

Mahesh Swaminathan, MB, BS, discusses whether the addition of obinutuzumab after 1 year of acalabrutinib/venetoclax is safe and effective in CLL.

With her collaborative ethos and patient-first focus, Lisa A. Carey, MD, ScM, FASCO, is driving innovation in breast cancer research and management.

Experts convene during an OncLive Peer Exchange to discuss the evolving treatment paradigm in HR-positive, HER2-negative breast cancer.

Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving considerations for treatment navigation in EGFR-mutant NSCLC.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends spanning CML, CLL, B-cell lymphomas, and other hematologic malignancies.

Alexander B. Olawaiye, MD, spotlights this phase 2 study evaluating bevacizumab plus relacorilant and nab-paclitaxel in platinum-resistant ovarian cancer.

Enfortumab vedotin plus pembrolizumab is the first perioperative regimen without chemotherapy to improve both EFS and OS in cisplatin-eligible MIBC.

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

Both the phase 3 STAR-221 trial and phase 2 EDGE-Gastric studies of domvanalimab plus zimberelimab in upper GI cancers are being discontinued.

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.